{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Miura Y"],"funding":["grants-in-aid from the Ministry of Education, Culture, Sports, Science and Technology (MEXT)/JSPS KAKENHI","Bristol-Myers Squibb K.K. and Ono Pharmaceutical Co., LTD"],"pagination":["16363"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9525600"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["12(1)"],"pubmed_abstract":["CD80 interact with CD28 and CTLA-4 on antigen-presenting cells, and function in the co-stimulatory signaling that regulates T cell activity. CTLA-4-Ig is used to treat RA by blocking co-stimulatory signaling. Chronic inflammatory arthritis was induced in D1BC mice using low-dose arthritogenic antigens and treated with CTLA-4-Ig. We performed histopathology of the joints and lymph nodes, serological examination for rheumatoid factors, and flow cytometric analysis of isolated synovial cells, including CD45<sup>-</sup> FLSs and CD45<sup>+</sup> synovial macrophages. CTLA-4-Ig treatment ameliorated the chronic inflammatory polyarthritis. There was a decrease in the number of infiltrating lymphoid cells in the joints as well as in the levels of RF-IgG associated with a decrease in the number of"],"journal":["Scientific reports"],"pubmed_title":["CTLA-4-Ig internalizes CD80 in fibroblast-like synoviocytes from chronic inflammatory arthritis mouse model."],"pmcid":["PMC9525600"],"funding_grant_id":["JP 20K17447","JP 26461470"],"pubmed_authors":["Kanazawa S","Miura Y","Maeda S","Isogai S"],"additional_accession":[]},"is_claimable":false,"name":"CTLA-4-Ig internalizes CD80 in fibroblast-like synoviocytes from chronic inflammatory arthritis mouse model.","description":"CD80 interact with CD28 and CTLA-4 on antigen-presenting cells, and function in the co-stimulatory signaling that regulates T cell activity. CTLA-4-Ig is used to treat RA by blocking co-stimulatory signaling. Chronic inflammatory arthritis was induced in D1BC mice using low-dose arthritogenic antigens and treated with CTLA-4-Ig. We performed histopathology of the joints and lymph nodes, serological examination for rheumatoid factors, and flow cytometric analysis of isolated synovial cells, including CD45<sup>-</sup> FLSs and CD45<sup>+</sup> synovial macrophages. CTLA-4-Ig treatment ameliorated the chronic inflammatory polyarthritis. There was a decrease in the number of infiltrating lymphoid cells in the joints as well as in the levels of RF-IgG associated with a decrease in the number of","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Sep","modification":"2026-07-14T15:49:49.383Z","creation":"2025-02-19T00:23:47.616Z"},"accession":"S-EPMC9525600","cross_references":{"pubmed":["36180526"],"doi":["10.1038/s41598-022-20694-7"]}}